Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/31515134 below:

Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey

Affiliations

• ¹ National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: mti6@cdc.gov.
• ² National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; Synergy America, Inc., Duluth, Georgia.
• ³ National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
• ⁴ National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.

• PMID: 31515134
• DOI: 10.1016/j.jadohealth.2019.07.003

Item in Clipboard

Nancy M McClung et al. J Adolesc Health. 2019 Dec.

• ¹ National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: mti6@cdc.gov.
• ² National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; Synergy America, Inc., Duluth, Georgia.
• ³ National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.
• ⁴ National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia.

• PMID: 31515134
• DOI: 10.1016/j.jadohealth.2019.07.003

Item in Clipboard

Purpose: To monitor human papillomavirus (HPV) vaccine impact in the U.S., we evaluated quadrivalent vaccine (4vHPV)-type prevalence among females aged 14-34 years in the prevaccine (2003-2006) and vaccine (2013-2016) eras overall and by race/ethnicity in the National Health and Nutrition Examination Survey.

Methods: We analyzed HPV DNA prevalence in self-collected cervicovaginal specimens, demographic characteristics, sexual behavior, and self-reported/parent-reported vaccination status. We compared prevaccine to vaccine era 4vHPV-type prevalence, using unadjusted and adjusted prevalence ratios (PR and aPR) and 95% confidence intervals (CIs). PRs were calculated by race/ethnicity (non-Hispanic white [NHW], non-Hispanic black [NHB], and Mexican American [MA]). Overall aPRs were adjusted for race/ethnicity, lifetime sex partners, and poverty.

Results: Overall, 4,674 females had HPV typing results; 3,915 reported NHW, NHB, or MA race/ethnicity. Vaccination coverage of ≥1 dose was 53.9% among 14- to 19-year-olds (NHW 52.6%, NHB 58.1%, and MA 59.5%) and 51.5% among 20- to 24-year-olds (NHW 58.8%, NHB 45.0%, MA 33.8%). Among 14- to 19-year-olds, 4vHPV-type prevalence decreased overall (11.5% to 1.8%; aPR = .14 [CI: .08-.24]) and in NHW (PR = .14 [CI: .06-.29]), NHB (PR = .26 [CI: .12-.54]), and MA (PR = .13 [CI: .03-.53]). In 20- to 24-year-olds, 4vHPV-type prevalence decreased overall (18.5% to 5.3%; aPR = .29 [CI: .15-.56]) and in NHW (PR = .27 [CI: .11-.67]) and NHB (PR = .38 [CI: .18-.80]). No significant declines were observed in older age groups.

Conclusions: Within 10 years of vaccine introduction, 4vHPV-type prevalence declined 86% among 14- to 19-year-olds, with declines observed in NHW, NHB, and MA females, and 71% among 20- to 24-year-olds, with declines in NHW and NHB females. These extraordinary declines should lead to substantial reductions in HPV-associated cancers.

Keywords: HPV vaccine; Human papillomavirus; Public health.

Published by Elsevier Inc.

PubMed Disclaimer

• Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.

  Oliver SE, Unger ER, Lewis R, McDaniel D, Gargano JW, Steinau M, Markowitz LE. Oliver SE, et al. J Infect Dis. 2017 Sep 1;216(5):594-603. doi: 10.1093/infdis/jix244. J Infect Dis. 2017. PMID: 28931217 Free PMC article.

• High impact of quadrivalent human papillomavirus vaccine across racial/ethnic groups: National Health and Nutrition Examination Survey, 2003-2006 and 2015-2018.

  Stefanos R, Lewis RM, Querec TD, Gargano JW, Unger ER, Markowitz LE. Stefanos R, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2308378. doi: 10.1080/21645515.2024.2308378. Epub 2024 Feb 19. Hum Vaccin Immunother. 2024. PMID: 38372273 Free PMC article.

• Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.

  Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Rosenblum HG, et al. MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):415-420. doi: 10.15585/mmwr.mm7012a2. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33764964 Free PMC article.

• Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S.

  Hirth J, McGrath CJ, Kuo YF, Rupp RE, Starkey JM, Berenson AB. Hirth J, et al. Vaccine. 2018 Nov 29;36(50):7682-7688. doi: 10.1016/j.vaccine.2018.10.075. Epub 2018 Oct 28. Vaccine. 2018. PMID: 30377066 Free PMC article.

• The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

  Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H. Patel C, et al. Euro Surveill. 2018 Oct;23(41):1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737. Euro Surveill. 2018. PMID: 30326995 Free PMC article. Review.

• Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine.

  Schlecht NF, Diaz A, Nucci-Sack A, Shyhalla K, Shankar V, Guillot M, Hollman D, Strickler HD, Burk RD. Schlecht NF, et al. JAMA Netw Open. 2021 Aug 2;4(8):e2121893. doi: 10.1001/jamanetworkopen.2021.21893. JAMA Netw Open. 2021. PMID: 34424304 Free PMC article.

• Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States.

  Meites E, Stone L, Amiling R, Singh V, Unger ER, Derkay CS, Markowitz LE. Meites E, et al. Clin Infect Dis. 2021 Sep 7;73(5):885-890. doi: 10.1093/cid/ciab171. Clin Infect Dis. 2021. PMID: 33621333 Free PMC article.

• Evaluation of an Inpatient Postpartum Human Papillomavirus Immunization Program.

  Avni-Singer L, Oliveira CR, Torres A, Shapiro ED, Niccolai LM, Sheth SS. Avni-Singer L, et al. Obstet Gynecol. 2020 Nov;136(5):1006-1015. doi: 10.1097/AOG.0000000000004097. Obstet Gynecol. 2020. PMID: 33030866 Free PMC article.

• Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.

  Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Meites E, et al. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702. doi: 10.15585/mmwr.mm6832a3. MMWR Morb Mortal Wkly Rep. 2019. PMID: 31415491 Free PMC article.

• The E3 ubiquitin ligase RNF6 facilitates the progression of cervical cancer by inhibiting the Hippo/Yap pathway.

  Liu Y, Zhou J, Liu W, Le Y, Zhang L, Zhang Z, Zhou L, Li L. Liu Y, et al. Cell Div. 2024 Nov 17;19(1):32. doi: 10.1186/s13008-024-00136-8. Cell Div. 2024. PMID: 39551725 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3